首页> 外文OA文献 >Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology.
【2h】

Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology.

机译:L-687,414((+)-顺-4-甲基-HA-966)是一种作用于甘氨酸位点的NMDA受体拮抗剂,对脑葡萄糖代谢和皮质神经元形态缺乏影响。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

1. N-methyl-D-aspartate (NMDA) receptor ion channel antagonists have been reported to cause pronounced increases in cerebral glucose metabolism (CMRglc) and transient reversible vacuolation within pyramidal cortical neurones. The present studies examined in rats the effects of the NMDA receptor antagonist, L-687,414 (R-(+)-cis-4-methyl-3-amino-l-hydroxypyrolid-2-one (+)-cis-4-methyl-HA-966) on regional CMRglc and cortical neuronal morphology. 2. L-687,414 was given as a steady state intravenous infusion for 4 h in a neuroprotective dose regime of 17.5 mg free base kg-1 bolus followed by 225 micrograms kg-1 min-1 (n = 8) or at the higher dose rate of 35 mg kg-1 bolus followed by 440 micrograms kg-1 min-1 (n = 10). Data were compared to a parallel series of experiments in rats given the NMDA receptor ion channel antagonist, dizocilpine for 4 h in the optimum intravenous neuroprotective dose-regime of 0.12 mg kg-1 bolus followed by 1.8 micrograms kg-1 min-1 (n = 8) or at the higher dose rate of 0.4 mg kg-1 bolus followed by 6 micrograms kg-1 min-1 (n = 4; morphology only studied). A saline-infused group of rats (n = 8) were used as controls. 3. CMRglc was studied by use of [14C]-2-deoxyglucose and autoradiography (n = 4 each group) whilst plasma drug levels were in a steady state during the final 45 min of the 4 h drug infusion.(ABSTRACT TRUNCATED AT 250 WORDS)
机译:1.据报道,N-甲基-D-天门冬氨酸(NMDA)受体离子通道拮抗剂可导致锥体皮质神经元内的脑葡萄糖代谢(CMRglc)和瞬时可逆空泡明显增加。本研究在大鼠中检查了NMDA受体拮抗剂L-687,414(R-(+)-顺-4-甲基-3-氨基-1-羟基吡咯烷-2-酮(+)-顺-4-甲基-HA-966)上的区域CMRglc和皮质神经元形态。 2.以17.5 mg游离碱kg-1推注的神经保护剂量方案,将L-687,414稳态静脉输注4小时,然后以225微克kg-1 min-1(n = 8)或更高剂量给予剂量为35 mg kg-1推注剂量,随后为440微克kg-1 min-1(n = 10)。将数据与在NMDA受体离子通道拮抗剂地佐西平以0.12 mg kg-1推注的最佳静脉内神经保护剂量方案给药4小时,然后以1.8微克kg-1 min-1(n = 8)或以0.4 mg kg-1推注的较高剂量率给药,然后以6微克kg-1 min-1给药(n = 4;仅研究形态)。盐水注射组的大鼠(n = 8)用作对照。 3.通过使用[14C] -2-脱氧葡萄糖和放射自显影(每组n = 4)研究了CMRglc,同时在输注4 h的最后45分钟内血浆药物水平处于稳定状态。(摘要截断于250话)

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号